Bibliography
- KEATINGS VM, COLLINS PD, SCOTT DM, BARNES PJ: Differences in interleukin-8 and tumor necrosis factor-α in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am. J. Respir. Crit. Care Med. (1996) 153(2):530-534.
- TAYLOR PC, WILLIAMS RO, FELDMANN M: Tumour necrosis factor α as a therapeutic target for immune-mediated inflammatory diseases. Curr. Opin. Biotechnol. (2004) 15(6):557-563.
- DE GODOY I, DONAHOE M, CALHOUN WJ, MANCINO J, ROGERS RM: Elevated TNF-α production by peripheral blood monocytes of weight-losing COPD patients. Am. J. Respir. Crit. Care Med. (1996) 153(2):633-637.
- VAN DER VAART H, KOETER GH, POSTMA DS, KAUFFMAN HF, TEN HACKEN NH: First study of infliximab treatment in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. (2005) 172(4):465-469.
- ARNOTT ID, McNEILL G, SATSANGI J: An analysis of factors influencing short-term and sustained response to infliximab treatment for Crohn’s disease. Aliment. Pharmacol. Ther. (2003) 17(12):1451-1457.
- PELEMAN RA, RYTILA PH, KIPS JC, JOOS GF, PAUWELS RA: The cellular composition of induced sputum in chronic obstructive pulmonary disease. Eur. Respir. J. (1999) 13(4):839-843.
- KEATINGS VM, BARNES PJ: Granulocyte activation markers in induced sputum: comparison between chronic obstructive pulmonary disease, asthma, and normal subjects. Am. J. Respir. Crit. Care Med. (1997) 155(2):449-453.
- KHARITONOV SA, BARNES PJ: Effects of corticosteroids on noninvasive biomarkers of inflammation in asthma and chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. (2004) 1(3):191-199.
- BARNES PJ: Chronic obstructive pulmonary disease * 12: new treatments for COPD. Thorax (2003) 58(9):803-808.
Websites
- www.goldcopd.com The GOLD Workshop report: global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease (updated 2004).
- www.remicade.com/pdf/HCP_PPI.pdf Data sheet on infliximab.